Eisai Patient Support

Current June 2026 form and EPS page identify enrollment, benefits verification and financial-assistance evaluation. The page offers prior-authorization and appeal information and Access and Reimbursement Manager support. Submit the completed form and requested insurance documents by the published fax; eligibility and payer decisions remain separate.

Current July 2026 form covers LEQEMBI infusion and LEQEMBI IQLIK with formulation-specific PAP, temporary supply and copay offerings. Select the appropriate sections and secure the required patient authorization. Current EPS page identifies LEQEMBI Companion and access/reimbursement support; enrollment does not assure coverage or program eligibility.

Current forms publish the same Suite 300 mailing destination for authorization revocation. Name the applicable program and follow its instructions. The forms also permit product-specific phone/fax contact through their respective enrollment contacts.

Operated by Sonexus Health Pharmacy Services, LLC; NPI 1861259194 and NCPDP 5942176 appear in current forms. LENVIMA EPS offers e-prescribing as an enrollment option. LEQEMBI form limits this pharmacy section to PAP and LEQEMBI infusion TSP evaluation. Use each product’s own form and fax; the pharmacy’s Suite 400A differs from Suite 300 authorization correspondence.

Published in the pharmacist coordination-of-benefits processing instructions at the coupon destination currently linked by EPS. The destination retains copyright 2023; the current link and older document vintage are recorded separately. No reimbursement amount or individual qualification is promised.

Published digital program-enrollment entry. Public application shell only; sign-in and submission were not tested. Follow formulation-specific offerings in the current form.

Current official page links this distinct IQLIK copay entry. It is not generalized to infusion copay enrollment. Public coupon-portal shell retrieved; no eligibility determination or submission was tested.